Compare
PRO DEX Inc vs Sight Sciences, Inc. vs Pulmonx Corp vs Apyx Medical Corp
| Latest fiscal year | PRO DEX Inc PDEX | Sight Sciences, Inc. SGHT | Pulmonx Corp LUNG | Apyx Medical Corp APYX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $77.55M | $77.36M | $90.50M | $52.84M |
| Revenue growth (YoY) | +16.5% | -3.1% | +8.0% | +9.9% |
| Gross margin | 31.4% | 86.2% | 74.2% | 62.5% |
| Operating margin | 16.8% | -48.0% | -59.3% | -12.2% |
| Net margin | 17.6% | -49.7% | -59.7% | -21.2% |
| Net income | $13.66M | -$38.43M | -$54.00M | -$11.21M |
| EPS (Diluted) | $4.12 | -$0.74 | -$1.33 | n/a |
| Operating cash flow | $7.24M | -$29.69M | -$32.38M | -$8.00M |
| Free cash flow | $6.76M | -$29.92M | -$32.83M | -$9.12M |
| Cash & equivalents | $8.19M | $91.97M | $69.75M | $31.74M |
| Total assets | $74.51M | $115.30M | $129.29M | $66.84M |
| Total liabilities | $26.88M | $51.36M | $75.17M | $52.01M |
| Shareholders' equity | $47.63M | $63.94M | $54.12M | $14.54M |
| Return on year-end equity | 28.7% | -60.1% | -99.8% | -77.1% |
| Shares outstanding | 3.19M | 53.49M | 41.67M | 41.79M |
Revenue, most recent five fiscal years
| Fiscal year | PRO DEX Inc | Sight Sciences, Inc. | Pulmonx Corp | Apyx Medical Corp |
|---|---|---|---|---|
| Latest | $77.55M Ended 2026-06-30 | $77.36M Ended 2025-12-31 | $90.50M Ended 2025-12-31 | $52.84M Ended 2025-12-31 |
| 1 year earlier | $66.59M Ended 2025-06-30 | $79.87M Ended 2024-12-31 | $83.79M Ended 2024-12-31 | $48.10M Ended 2024-12-31 |
| 2 years earlier | $53.84M Ended 2024-06-30 | $81.06M Ended 2023-12-31 | $68.67M Ended 2023-12-31 | $52.35M Ended 2023-12-31 |
| 3 years earlier | $46.09M Ended 2023-06-30 | $71.33M Ended 2022-12-31 | $53.66M Ended 2022-12-31 | $44.51M Ended 2022-12-31 |
| 4 years earlier | $42.04M Ended 2022-06-30 | $48.96M Ended 2021-12-31 | $48.42M Ended 2021-12-31 | $48.52M Ended 2021-12-31 |